Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Growth in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 175,300 shares, an increase of 255.6% from the December 15th total of 49,300 shares. Approximately 2.8% of the shares of the company are short sold. Based on an average trading volume of 272,300 shares, the days-to-cover ratio is currently 0.6 days.

Protagenic Therapeutics Stock Performance

NASDAQ PTIX traded down $0.00 during trading on Tuesday, hitting $0.47. 183,480 shares of the company’s stock traded hands, compared to its average volume of 185,735. The stock has a market capitalization of $3.35 million, a price-to-earnings ratio of -0.37 and a beta of 0.28. The business has a 50 day moving average of $0.58 and a 200-day moving average of $0.64. Protagenic Therapeutics has a 12-month low of $0.44 and a 12-month high of $1.87.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.